Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.66 |
| ▸ | RAB9A | P51151 | 11/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.66 |
| ▸ | RELA | Q04206 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 11/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773733 | 0.83 | TP53 (0.68) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL12692485 | 0.83 | SMN1; SMN2 (0.70) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL12970198 | 0.83 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL4147815 | 0.83 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL1728599 | 0.83 | SMN1; SMN2 (0.66) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL1692138 | 0.83 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL30059210 | 0.83 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL2496897 | 0.83 | TP53 (0.68) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| Bromide SCHEMBL3869607 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL12692390 | 0.81 | TP53 (0.70) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007039146-A1 | 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
| US-4224334-A | Antiinflammatory imidazothiazoles and thiazolopyrimidines | DIAMOND SHAMROCK CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4103016-A | Antiinflammatory imidazothiazoles and thiazolopyrimidines | DIAMOND SHAMROCK CORPORATION (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | NPC1 1153/4885RAB9A 3798/4885SMN1; SMN2 1109/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | NPC1 1153/4885RAB9A 3798/4885SMN1; SMN2 1109/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | NPC1 50/4885RAB9A 377/4885SMN1; SMN2 1856/4885 |
| US-20140206662-A1 | Imidazopyridine Compounds | SSB, NFKBIA, TPMT | NPC1 2286/4885RAB9A 3886/4885SMN1; SMN2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.